NovaGo Therapeutics raises CHF 24 M

NovaGo Therapeutics is developing anti-Nogo-A antibodies aimed at a first regenerative treatment for acute spinal cord injuries. The biotech closed a Series B round of CHF 24 million (USD 30 million), co-led by Neurimmune and Pureos and complemented by non-dilutive funding, to fund a 120-patient proof-of-concept study.

Announced on
Round
Series B
Amount
CHF 24 M
Location
Schlieren, canton of Zurich
Sector
Biotech & life sciences

Investors

  • Neurimmune lead
  • Pureos Bioventures lead
  • Swiss Paraplegic Foundation
  • Wings for Life

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic